Announcements Trials
Browse Landscape

Phase

Phase 2 2Phase 1/2 1

Status

Recruiting 2Active not recruiting 2

Sponsor Class

OTHER 3INDUSTRY 1

Study Type

Interventional 3Observational 1

Sponsor

Cancer Type

Breast 4CNS 1

Conditions

Breast Neoplasms 3137Neoplasms 2474Carcinoma, Non-Small-Cell Lung 1883Prostatic Neoplasms 1641Colorectal Neoplasms 1432Lung Neoplasms 1308Multiple Myeloma 937Neoplasm Metastasis 926Leukemia, Myeloid, Acute 885Pancreatic Neoplasms 860Ovarian Neoplasms 814Melanoma 791Carcinoma, Hepatocellular 743Stomach Neoplasms 647Recurrence 640Brain Neoplasms 640Squamous Cell Carcinoma of Head and Neck 638Head and Neck Neoplasms 609Glioblastoma 573Uterine Cervical Neoplasms 549Lymphoma 549Triple Negative Breast Neoplasms 514Precursor Cell Lymphoblastic Leukemia-Lymphoma 511Carcinoma, Renal Cell 504Endometrial Neoplasms 467Hematologic Neoplasms 464Urinary Bladder Neoplasms 462Colonic Neoplasms 447Lymphoma, Non-Hodgkin 437Sarcoma 436

Interventions

tucatinib 1pertuzumab 1atezolizumab 1Trastuzumab 1Fulvestrant 1Alpelisib 1Ado-Trastuzumab Emtansine 1

Date Range

30 days90 days1 yearAll

Options

Has results Has announcements

Clinical Trials

4 trials
RecentStart dateEnrollment
HER2-positive Metastatic Breast Cancer × 1 year × Clear all
NCT06595563 2026-05-07

ZEPHIR-02

Jules Bordet Institute

Phase 2 Recruiting
87 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT03417544 2026-04-27

Atezolizumab + Pertuzumab + Trastuzumab In CNS Mets In BC

Dana-Farber Cancer Institute

Phase 2 Active not recruiting
19 enrolled 26 charts
BreastCNS

HER2-positive Metastatic Breast Cancer

NCT06551116 2026-04-07

QuantifyHER: Quantitative Immunofluorescence and/or RT-qPCR for Measuring HER2 in HER2-low Metastatic Breast Cancer

Abramson Cancer Center at Penn Medicine

Recruiting
200 enrolled
Breast

HER2-positive Metastatic Breast Cancer

NCT05230810 2026-03-16

Clinical Trial of Alpelisb and Tucatinib in Patients With PIK3CA-Mutant HER2+ Metastatic Breast Cancer.

Criterium, Inc.

Phase 1/2 Active not recruiting
40 enrolled
Breast

HER2-positive Metastatic Breast Cancer

Data powered by HemOnc (CC BY 4.0) Colophon âš¡